First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors.
- DOI
- 10.1007/s10637-026-01636-w
- Published
- 2026 Sep 14
- Container
- Investigational new drugs
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10637-026-01636-w,
title = {First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors.},
author = {Galot R and Castel-Ajgal Z and Kotecki N and Jungels C and Delord JP and Korakis I and El-Farouk S and Jouffroy-Zeller C and Quesnel A and Duarte C and Taamma A and Maurin T and Lecru L and Mousson A and Blanchard O and Blayo AL and Lenne N and Schann S and Leroy X and Cuillerot JM and Le Tourneau C and Machiels JP},
year = {2026},
journal = {Investigational new drugs},
doi = {10.1007/s10637-026-01636-w},
url = {https://doi.org/10.1007/s10637-026-01636-w}
}RIS
TY - JOUR TI - First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors. AU - Galot R AU - Castel-Ajgal Z AU - Kotecki N AU - Jungels C AU - Delord JP AU - Korakis I AU - El-Farouk S AU - Jouffroy-Zeller C AU - Quesnel A AU - Duarte C AU - Taamma A AU - Maurin T AU - Lecru L AU - Mousson A AU - Blanchard O AU - Blayo AL AU - Lenne N AU - Schann S AU - Leroy X AU - Cuillerot JM AU - Le Tourneau C AU - Machiels JP PY - 2026 JO - Investigational new drugs DO - 10.1007/s10637-026-01636-w UR - https://doi.org/10.1007/s10637-026-01636-w ER -
APA
R, G., Z, C., N, K., C, J., JP, D., I, K., S, E., C, J., A, Q., C, D., A, T., T, M., L, L., A, M., O, B., AL, B., N, L., S, S., X, L., JM, C., C, L. T., & JP, M. (2026). First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors.. Investigational new drugs. https://doi.org/10.1007/s10637-026-01636-w
Source records
- pubmed · retrieved 2026-09-25T18:21:45.663Z